Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16871
Country/Region: Nigeria
Year: 2016
Main Partner: Institute of Human Virology, Nigeria
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $20,099,773 Additional Pipeline Funding: $13,626,019

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $8,006,586
Care: Orphans and Vulnerable Children (HKID) $4,457,856
Care: TB/HIV (HVTB) $1,545,588
Care: Pediatric Care and Support (PDCS) $1,340,829
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $3,882,336
Treatment: Pediatric Treatment (PDTX) $866,578
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 31
GEND_GBV Age/Sex: <10 Male 2017 33
GEND_GBV Age/Sex: 10-14 Female 2017 493
GEND_GBV Age/Sex: 10-14 Male 2017 554
GEND_GBV Age/Sex: 15-19 Female 2017 31
GEND_GBV Age/Sex: 15-19 male 2017 27
GEND_GBV Age/Sex: 20-24 Female 2017 135
GEND_GBV Age/Sex: 20-24 Male 2017 22
GEND_GBV Age/Sex: 25-49 Female 2017 11,496
GEND_GBV Age/Sex: 25-49 Male 2017 5,117
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 12,751
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 4,091
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 14,165
GEND_GBV Number of people receiving post-GBV care 2017 18,256
GEND_GBV Sum of Age/Sex Disaggregates 2017 1,111
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 71,573
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 63,454
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 670,664
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 365,447
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,171,138
HTS_TST Service Delivery Point (Community): Mobile testing 2017 210,454
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,372
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,375
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 704
HTS_TST Service Delivery Point (Facility): Other PITC 2017 48
HTS_TST Service Delivery Point (Facility): Outpatient 2017 397,099
HTS_TST Service Delivery Point (Facility): Pediatric 2017 134,781
HTS_TST Service Delivery Point (Facility): PMTCT 2017 259,931
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 16,363
HTS_TST Service Delivery Point (Facility): VCT 2017 148,984
HTS_TST Service Delivery Point (Facility): VMMC 2017 27
HTS_TST Sum of Aggregated Age/Sex <15 2017 135,027
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,036,111
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,171,138
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Female 2017 4
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Male 2017 3
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Female 2017 919
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Male 2017 104
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,965
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,677
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 19,103
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 14,450
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 43
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 43
LAB_PT CD4: Number of laboratories that perform this testing 2017 43
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 6
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 6
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 6
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 63
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 63
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 63
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 6
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 6
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 6
OVC_SERV Age/Sex: 18+ Female 2017 4,960
OVC_SERV Age/Sex: 18+ Male 2017 4,954
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 44,644
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 44,632
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 99,190
OVC_SERV Sum of Age/Sex disaggregates 2017 9,914
PMTCT_ART Already on ART at beginning of current pregnancy 2017 3,525
PMTCT_ART New on ART 2017 5,155
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 259,744
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 5,184
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3,487
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 87
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 109
PMTCT_EID Sum of Infant Age disaggregates 2017 8,671
PMTCT_STAT By: Known positives at entry 2017 3,764
PMTCT_STAT By: Number of new positives identified 2017 5,221
PMTCT_STAT Number of new ANC and L&D clients 2017 273,005
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 259,744
PMTCT_STAT Sum of Positives Status disaggregates 2017 8,985
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 29
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 829
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 26
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 719
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,792
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,603
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 4,338
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3,901
TB_SCREENDX Screen Result: Screened Positive for TB 2017 4,818
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 141,575
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 55,663
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,577
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 7,154
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 208,969
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 182
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,016
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 241
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5,057
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 9,496
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 10,593
TX_CURR Aggregated Age/Sex: <15 Female 2017 6,771
TX_CURR Aggregated Age/Sex: <15 Male 2017 6,075
TX_CURR Aggregated Age/Sex: 15+ Female 2017 110,453
TX_CURR Aggregated Age/Sex: 15+ Male 2017 46,036
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 169,335
TX_CURR Sum of Aggregated Age/Sex <15 2017 12,846
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 156,489
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 169,335
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,729
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,510
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 17,456
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 15,391
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 36,086
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 36,086
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 175,523
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 152,662
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,655
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,696
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 104,117
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 43,194
TX_PVLS Numerator: Indication: Routine 2017 122,113
TX_PVLS Numerator: Indication: Targeted 2017 30,549
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,952
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,956
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 119,921
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 49,694
TX_PVLS_den Denominator: Indication: Routine 2017 140,382
TX_PVLS_den Denominator: Indication: Targeted 2017 35,141
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,421
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,587
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 54,539
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22,072
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 79,619
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 93,670
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,674
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,866
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64,157
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 25,973
Cross Cutting Budget Categories and Known Amounts Total: $3,130,417
Economic Strengthening $297,187
Food and Nutrition: Commodities $100,000
Human Resources for Health $345,077
Education $100,000
Motor Vehicles: Purchased $250,000
Key Populations: MSM and TG $50,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: Sex Workers $79,698
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $956,061
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $50,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Renovation $860,000
Water $42,394